# Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

> **NCT01575873** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 795 (actual)

## Conditions studied

- Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Placebo for risendronate
- **DRUG:** Risendronate
- **DRUG:** Placebo for denosumab

## Key facts

- **NCT ID:** NCT01575873
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-28
- **Primary completion:** 2016-06-21
- **Final completion:** 2017-06-29
- **Target enrollment:** 795 (ACTUAL)
- **Last updated:** 2018-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01575873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01575873, "Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01575873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*